Literature DB >> 3293869

Amiodarone therapeutic plasma concentration monitoring. Is it practical?

T Maling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3293869     DOI： 10.2165/00003088-198814060-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  17 in total

1.  Individual variability of amiodarone distribution in plasma and erythrocytes: implications for therapeutic monitoring.

Authors:  T J Maling; R W Siebers; C D Burgess; C Taylor; G Purdie
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

2.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency.

Authors:  J Morganroth; E L Michelson; L N Horowitz; M E Josephson; A S Pearlman; W B Dunkman
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

Review 4.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

5.  Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording.

Authors:  E L Michelson; J Morganroth
Journal:  Circulation       Date:  1980-04       Impact factor: 29.690

Review 6.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

7.  Multicenter controlled observation of a low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Collaborative Group for Amiodarone Evaluation.

Authors: 
Journal:  Am J Cardiol       Date:  1984-06-01       Impact factor: 2.778

8.  Plasma and red blood cell concentrations of amiodarone during chronic therapy.

Authors:  J J Heger; E B Solow; E N Prystowsky; D P Zipes
Journal:  Am J Cardiol       Date:  1984-03-15       Impact factor: 2.778

9.  The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone.

Authors:  N M Debbas; C du Cailar; R S Bexton; J G Demaille; A J Camm; P Puech
Journal:  Br Heart J       Date:  1984-03

10.  Amiodarone: correlation of serum concentration with suppression of complex ventricular ectopic activity.

Authors:  N D Mostow; L Rakita; T R Vrobel; D L Noon; J Blumer
Journal:  Am J Cardiol       Date:  1984-09-01       Impact factor: 2.778
View more
  3 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Amiodarone in a newborn with ventricular tachycardia and an intracardiac tumor: adjusting the dose according to an individualized dosing regimen.

Authors:  T Bouillon; H Schiffmann; D Bartmus; U Gundert-Remy
Journal:  Pediatr Cardiol       Date:  1996 Mar-Apr       Impact factor: 1.655

Review 3.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.